K.A.J. van Schie
- Immunogenicity of therapeutic antibodies
- Immunological mechanisms & clinical consequences
S.M. van Ham
- Award date
- 12 October 2017
- Number of pages
- Document type
- PhD thesis
- Faculty of Science (FNWI)
- Swammerdam Institute for Life Sciences (SILS)
Monoclonal antibody therapy has revolutionized the treatment of many diseases, including chronic inflammatory diseases and cancer. Antibody therapy can unfortunately also elicit an unwanted immune response, leading to anti-drug antibodies (ADA). It is well known that ADA can lower the level of free drug, which may lead to a reduced clinical response. Additionally, for some antibody therapeutics, more adverse events are reported in ADA positive patients. A rather neglected result of immunogenicity is the formation of immune complexes between drug and ADA that likely occurs in all ADA positive patients. Although the high dosages drug and ADA could possibly lead to a very high amount of immune complexes, the biological and clinical effects of these complexes are largely unknown. The aim of this thesis is to provide a detailed characterization of the ADA response and its associated immune complex formation, to better understand the causes and mechanisms behind the adverse clinical observations.
Thesis (complete) (Embargo up to and including 12 October 2018)
Chapter 7: Complexes of drug and anti-drug antibodies cause limited immune activation due to a restricted anti-idiotype response (Embargo up to and including 12 October 2018)
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.